Ovid Therapeutics

Yahoo Finance • 4 days ago

Ovid spikes as Wedbush moves to Outperform on lead asset

[Wall Street sign in Lower Manhattan, NYC] georgeclerk/iStock via Getty Images Ovid Therapeutics (NASDAQ:OVID [https://seekingalpha.com/symbol/OVID]) added ~13% on Thursday after Wedbush revised its rating to Outperform from not rated, ci... Full story

Yahoo Finance • 10 days ago

Ovid rises after positive results from epilepsy study

[Doctor writing word Epilepsy with marker, Medical concept] Michail_Petrov-96/iStock via Getty Images * Ovid Therapeutics (NASDAQ:OVID [https://seekingalpha.com/symbol/OVID]) stock rose after encouraging results from its early stage stu... Full story

Yahoo Finance • 12 days ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 17 days ago

Mixed Catalysts Drive After-Hours Moves In MRM, LEXX, SHOT, AQST, And OVID

(RTTNews) - Several small-cap names posted sharp gains in Thursday's after-hours session, driven by fresh corporate updates, clinical developments, and strategic pivots. Below are five stocks that stood out for their notable post-close mov... Full story

Yahoo Finance • 2 months ago

Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating

Investing.com - Lucid Capital Markets initiated coverage on Ovid Therapeutics Inc (NASDAQ:OVID) with a Buy rating and a $5.50 price target on Wednesday. The target represents significant upside potential for the $38.9 million market cap co... Full story

Yahoo Finance • 3 months ago

Solvonis chair to participate in biotech leadership panel

LONDON - Solvonis Therapeutics plc (LSE:SVNS) Chairman Dennis Purcell will join a panel discussion at an investor event hosted by Lucid (NASDAQ:LCID) Capital Markets on Thursday, July 17, the clinical-stage biopharmaceutical company announ... Full story

Yahoo Finance • 4 months ago

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today... Full story

Yahoo Finance • 4 months ago

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on T... Full story

Yahoo Finance • 7 months ago

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appoin... Full story

Yahoo Finance • 7 months ago

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, Presid... Full story

Yahoo Finance • 8 months ago

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will parti... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash runway into 2026 Clinical trials study... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid Ovid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash runway into 2026 while simultaneously reta... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today anno... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today ann... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today ann... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics to Participate in Upcoming September Investor Conferences

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today anno... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude NicaiseMeg Alexander promoted to Chief Strategy Officer Ovid str... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics Added to Russell 3000® Index

NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders,... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

Ovid Therapeutics Inc. Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseases Long-term data supporting soticlestat safety, tolerability and seizure-reduction efficacy presen... Full story